Why Mirati Therapeutics Is A Dangerous Rival To Amgen In Colon Cancer

Why Mirati Therapeutics Is A Dangerous Rival To Amgen In Colon Cancer

Mirati could beat Amgen to market with a KRAS-blocking colon cancer drug, an analyst said Monday as MRTX stock popped.